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Commentary on ‘Use of Colour Duplex Ultrasound as a First Line Surveillance Tool
Following Evar is Associated with a Reduction in Cost without Compromising
Accuracy’
A. Chaudhuri*
Bedfordshire Vascular Unit, Bedford Hospital NHS Trust, Kempston Road, Bedford MK42 9DJ, United KingdomThe opening statement of the abstract, in this article by
McDonnell et al., underpins how clinicians can get stuck in their
practice. Why are patients subjected to repeat CT scans, whenmany
studies, including this one, show this to be unnecessary and
pointlessly expensive?
The aim of surveillance is simply to look at two things: form, i.e.
structural integrity and position of the endograft, and function, i.e.
continued aneurysm exclusion, endoleaks and stenoses/occlusions
in limbs and related vessels. The oft repeated cliché that a CT scan
equates to 300 chest radiographs (CXRs) seems to be lost in themix,
by perhaps blasé clinicians who simply carry on as is, possibly
because EVAR is undertaken in older patients where such consid-
erations might be considered irrelevant. If we scrutinise this
further, the radiation dosage from abdominal CT scan is 8 mSv, and
from a CXR 0.02 mSv, making the factor actually 4001! Further-
more, there are issues with contrast dosage in someone with
borderline renal function, and the potential cancer risk associated
with CT.1If small aneurysm EVAR is taken up (as suggested by the
CAESAR and PIVOTAL trials)2and therefore likely for younger
patients, the latter risks cannot be ignored.
A combination of abdominal X-ray (AXR) and ultrasound (US)
therefore conveniently addresses both form and function issues,
and as the authors suggest, relatively newer modalities such as
contrast-enhanced (CE) US may not be required. There are,
however, studies suggesting the beneﬁts of CEUS, and, where
appropriate, MRA as referenced (though I cannot see this driving
the need for more MR-compatible devices, yet another aspect of
device evolution). There will be issues with operator dependence
with the former and cost/patient compliance with the latter.
This paper looks at EVAR surveillance only, without muddying
the picture by adding FEVAR, which is entirely reasonable.
However, there were no AXRs undertaken thereafter, and the
authors have ignored the‘form’aspect of the surveillance package
without any strong reason to support it. For the sake of the paper, it
would be reasonable to accept the CT as the surrogate for the AXR,DOI of original article: 10.1016/j.ejvs.2012.05.008.
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interesting to note that though 5 type 1 endoleaks were noted on
CDUS, only 3 were correlated on CTA, and the discrepancy high-
lights the issues with US interpretation. In addition, though CDUS
picked up more type 2 endoleaks than CTA, this may become
irrelevant from a practical point as most type 2 endoleaks will be
either insigniﬁcant3or not treated anyway.4Furthermore, even
though endotensionwas actually noted to be due to a lumbar type 2
endoleak, the authors missed the opportunity for considering
laparoscopic clipping, subjecting the patient to open operation,
therefore defeating the minimally invasive purpose of the overall
intervention. Directionality of a type 2 endoleak, and importantly
sac size are issues that guide intervention.4,5
The authors have undertaken a very useful cost savings anal-
ysis and that along with the clinical results should provide
enough impetus to make those institutionalised into routine post-
EVAR CT think about changing their practice, perhaps with some
incentive from their managers! I would have liked to have seen
a per patient cost-savings ﬁgure like that referenced, as that
would be a constant.
Our approach is to use just a single post-operative CT angiogram
(CTA) as a prudent‘baseline’for further scans using only AXR/CDUS
thereafter (and hypothetically one could look to push this even
further by opting for a non-CT approach- especially if EVAR
completion angiography is normal).6 We opt for CTA only when
there is any doubt with the imaging, which is usually US, as indi-
cated by the 6.1% of CDUS that was‘limited’. However, sac size not
being picked up on 37% of CTAs in this paper is staggeringly high.
Our own stipulation is that all surveillance imaging should be
undertaken/reported only by a vascular radiologist/technologist
and no other, as this has a bearing on (a) what (b) how things are
looked at and (c) get reported. The other issue this raises is whether
all units undertaking EVAR actually maintain a database of the scan
reports or not.
It is well worth the reader recapitulating these issues that have
been comprehensively outlined in the ESVS AAA guidelines,2
though AXR undertaken in conjunction with CTA (as recom-
mended) is possibly redundant, perhaps even wasteful, as 3D CT
reconstruction is more than capable of recreating good quality
multi-angle AXRs, which is our experience.d by Elsevier Ltd. All rights reserved.
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